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ABSTRACT  
PURPOSE: Tumor cell heterogeneity and microenvironment represent major 
hindering factors in the clinical setting toward achieving the desired selectivity and 
specificity to malignant tissues for molecularly targeted cancer therapeutics. In this 
study, the cellular and molecular evaluation of several delocalized lipophilic cation 
(DLC)-functionalized carborane compounds as innovative anticancer agents is 
presented.  
METHODS: The anticancer potential assessment of the DLC-carboranes was 
performed in established normal (MRC-5, Vero), cancer (U-87 MG, HSC-3) and 
primary glioblastoma cancer stem (EGFR
pos
, EGFR
neg
) cultures. Moreover, the 
molecular mechanism of action underlying their pharmacological response is also 
analyzed.  
RESULTS: The pharmacological anticancer profile of DLC-functionalized 
carboranes is characterized by: a) a marked in vitro selectivity, due to lower 
concentration range needed (ca. 10 fold) to exert their cell growth-arrest effect on U-
87 MG and HSC-3, as compared with that on MRC-5, Vero; b) a similar selective 
growth inhibition behavior towards EGFR
pos
 and EGFR
neg
 cultures (>10 fold 
difference in potency) without, however, the activation of apoptosis in cultures; c) 
notably, in marked contrast to cancer cells, normal cells are capable of recapitulating 
their full proliferation potential following exposure to DLC-carboranes; and, d) such 
pharmacological effects of DLC-carboranes has been unveiled to be elicited at the 
molecular level through activation of the p53/p21 axis.  
CONCLUSIONS: Overall, the data presented in this work indicates the potential of 
the DLC-functionalized carboranes to act as new selective anticancer therapeutics that 
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may be used autonomously or in therapies involving radiation with thermal neutrons. 
Importantly, such bifunctional capacity may be beneficial in cancer therapy.  
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INTRODUCTION 
Integral to the demand for the continuous improvement of the balance between 
benefits, (i.e. preferable tumor cell toxicity) and risks, (i.e. minimization of harmful 
side effects), the gold standard for modern cancer pharmacology is set by the need to 
develop chemotherapeutic agents that leave unaffected normal human cells while 
effectively targeting and destroying malignant tissues with a high degree of selectivity 
[1]. Cancer cell heterogeneity that contributes to therapy failure is based on molecular 
and genomic facets which allow a cancer cell to develop peculiar molecular biology 
and genome function within the context of the surrounding normal cell environment. 
Although various approaches have been developed thus far aiming to deliver 
molecularly-targeted innovative anticancer therapeutics and to minimize cancer drug 
resistance, the main problem of achieving selectivity and specificity for tumor cell 
cytotoxicity still remains elusive. It has been suggested that as long as technological 
advancements empower the translational medicine capacity in enabling the 
pharmacological exploitation of cancer cell molecular and genomic knowledge, the 
advances to therapeutically overcome heterogeneity and to target the tumor cell 
microenvironment will occur at increasing rates [2-10]. A major milestone towards 
organelle-specific drug delivery was reached by the discovery of delocalized 
lipophilic cations (DLCs) [11]. These molecular structures are guided selectively 
towards tumors by the higher mitochondrial transmembrane potential (~60 mV 
difference) that is consequent to the correspondingly higher metabolic activity of 
cancer cells relative to that of normal cells [12-16]. The resonance-stabilized 
delocalization of the positive charge of DLCs, coupled with their inherent 
lipophilicity, leads to a decrease in the cost associated with the free energy change 
that accompanies the diffusion of DLCs through cell membranes, and provides the 
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driving force for their observed highly selective accumulation (>100 fold) in the 
mitochondrial matrix of cancer cells [13,17,18] and the associated high (>5 fold) 
difference between their cytoplasmic and extracellular concentrations [11]. Towards 
the development of highly selective target-specific anticancer agents that are 
applicable to boron neutron capture therapy (BNCT) of cancer, this study builds on 
preliminary evaluations that indicated the selective accumulation of boronated DLC 
compounds in cancer cells [19,20].  In particular, the experimental work focuses on 
the pharmacological evaluation at cellular and molecular level of four of these boron 
molecules, the molecular design of which combines the tumor-cell specificity of 
DLCs with the high boron content of carborane structures [20]. The DLC-
functionalized carboranes exhibit high growth-arrest selectivity towards cancer cell 
lines (U-87 MG, HSC-3) including primary glioblastoma (GBM) cancer stem cells, in 
marked contrast to their effect on normal (MRC-5, Vero); importantly, only normal 
cells are capable of recapitulating their full proliferation potential after exposure to 
DLC-carboranes in culture. Such cancer cell behavior upon exposure to DLC-
carboranes has been shown to happen without induction of apoptosis in the cultures. 
Moreover, molecular gene expression profiling has indicated that the DLC-carboranes 
exert their pharmacological properties through the activation of the p53/p21 axis, a 
crucial molecular pathway long known to control cell cycling and growth arrest. 
Overall, these results present for the first time evidence that target specific DLC-
functionalized carborane compounds possess an interesting antitumor capacity as 
standalone  cancer therapeutics, in addition to their capacity to act as BNCT agents; 
potential synergies arising from such combined pharmacological effects render these 
DLC-carboranes candidate materials for further investigation and clinical evaluation 
in cancer therapy. 
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MATERIALS AND METHODS 
Cell cultures 
The already established permanent cancer model (U-87 MG, HSC-3) along with 
normal (MRC-5, Vero) cell lines stored and used in a routine manner in our 
laboratory (Aristotle University of Thessaloniki) were applied throughout this study. 
Malignant U-87 MG (human epithelial glioblastoma grade IV-astrocytoma) and HSC-
3 (human oral squamous carcinoma) cells, along with the normal MRC-5 (human 
fetal lung fibroblasts) and Vero (monkey kidney) cell lines were grown in culture (37 
o
C; humidified atmosphere containing 5% v/v CO2) in DMEM medium supplemented 
with 10% (v/v) FBS, 100 μg/mL of penicillin and 100 μg/mL of streptomycin. To 
allow the continuous logarithmic phase of cell growth in culture, cell lines were 
detached before reaching ca. 80% confluency (every 2-3 days) with trypsin-EDTA 
(0.25% w/v, Life Technologies). The DLC-carborane compounds under consideration 
(Figure 1) were previously synthesized by our group [20] and dissolved in DMSO and 
stored at 4 
o
C. Each cell culture was treated accordingly, as shown below and under 
figures (DMSO concentration ≤ 0.2% v/v). 
 
Cell propagation in established cell lines and cytotoxicity assessment  
The established malignant (U-87 MG and HSC-3) and normal (MRC-5 and Vero) cell 
lines were seeded in a 24-well plate at an initial concentration of 1x10
5 
cells/mL and 
allowed to stand for 3 h before the addition of DLC-carborane compounds at specified 
concentrations in the range 5x10
-5
 M to 1x10
-7
 M. To estimate the IC50 of each 
compound for each cell line, cells were allowed to grow for additional 48 h before 
being harvested by trypsinization and subsequently counted (cell density; number of 
cells/mL) with the aid of the optical microscope (Neubauer counting champers). Cell 
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growth is expressed as a percentage relative to that for the untreated control culture. 
Cell death was also determined using the trypan blue dye-exclusion method [21]. 
 
Cytotoxicity evaluation in primary GBM cancer stem cells (CSCs) (EGFR
neg
 and 
EGFR
pos
) 
Two primary GBM CSC cultures (EGFR
neg
 and EGFR
pos
) that had been isolated and 
characterized previously by Galli et al., [22] were evaluated after exposure to BOR2, 
BOR3 or BOR4. For their proper propagation, EGFR
neg
 cells, which grow in 
monolayers, and EGFR
pos
 cells, which grow in neurospheres, were each plated (25 
cm
2 
tissue culture flask) at clonal density (2500-5000 cells/cm
2) in Dulbecco’s 
modified Eagle’s medium/F-12 medium containing 20 ng/mL of each EGF and 
fibroblast growth factor (FGF2; Peprotech, Rocky Hill, NY). The cell proliferation 
capacity of primary cell lines that had been treated with DLC-carborane compounds 
(1x10
-7
 M to 1x10
-4
 M) was assessed by means of the MTT colorimetric assay, which 
measures cell viability with reference to the capability of metabolically active cells to 
reduce the water-soluble yellow MTT into the water-insoluble purple formazan 
[23,24]. EGFR
neg
 or EGFR
pos
 cells, both at the number of 1.5x10
4
 cells, were seeded 
overnight in 200 μL of culture medium using a 96-well plate pre-coated with 50 μL 
MatrigelTM (Becton and Dickinson, San Jose, CA) was removed just before the 
seeding of cells). Following cell attachment to the plate (3 h), BOR2, BOR3 and 
BOR4 were added separately at specified concentrations (1x10⁻
7
 M to 1x10⁻⁴ M) and 
the cells were allowed to grow for further 48 h. After this time, 20 μL of a 5 mg/mL 
solution of MTT that had been warmed and homogenized was added to each well. 
After 1 h, the insoluble, purple formazan was dissolved by adding 50 μL of DMSO. 
The 96 well-plate was covered with aluminum foil and agitated for 15 min in a plate 
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shaker before quantification by spectrophotometry (plate reader, 570 nm). Cell-free 
wells provided the controls for each compound and medium [24]; results, from at least 
two independent experiments, are expressed as percentage cell growth relative to that 
determined for corresponding untreated control cultures. 
 
Immunocytochemistry (ICC) assay 
For the detection of ki-67 proliferation and that of active caspase-3 apoptosis markers, 
a specified number of EGFR
neg 
cells (1.5 x 10
4
 cells at final cell culture volume 1 mL) 
was plated onto Matrigel-coated glass coverslips (12 mm diameter) in a 24 well tissue 
culture plate [22,25].  After 2-3 h, the BOR3 and BOR4 DLC-carboranes were added 
at their IC50 concentration, which had been determined by means of the MTT assay, 
and the cells were allowed to further proliferate for 24 or 48 h. The medium was 
removed and cells were fixed with 300 μL of PFA 4% (20 min; RT) and washed twice 
with cold PBS 1x. The coverslips were transferred to a new 24-well plate, the cells 
were permeabilized with 400 μL of 0.1× Triton lysis buffer (10 min) and incubated (2 
h, 37 
oC) with 250 μL of primary rabbit anti-caspase-3 (Cell Signaling, Denver, MA) 
and rabbit anti-ki-67 (Novocastra) antibodies that had been diluted with NGS 10 % 
(normal goat serum) to a respective final concentration of 1:400 and 1:1000 (v/v). 
Each well was washed twice with 300μL PBS 1× and incubated for 45 min on the 
orbital shaker with 250 μL of the secondary rabbit Alexa 488 nm (Molecular Probes, 
Invitrogen) antibody, which had been added at a final concentration of 1:1000 (v/v); 
plates were covered with aluminum foil. Each well was washed three times with 300 
μL PBS 1× and the nuclei of cells were stained with 300 μL of DAPI (Fluka, Buchs, 
Switzerland) for 10 min at room temperature. The supernatant was removed, the cells 
were washed three times with 300 μL of PBS 1× and the cover slips were finally 
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transferred onto glass slides, and arranged according to incubation time with the 
DLC-carborane compounds and the marker of interest. The coverslips were fixed with 
the glue-like Fluor Save Reagent (Merck, Calbiochem, Darmstadt, Germany) and 
covered with a micro cover glass. The levels of markers were determined 
quantitatively under the Νikon Εclipse Ε600 fluorescence microscope by counting a 
minimum number of one thousand cells at 330 - 420 nm for the DAPI staining and at 
450 -520 nm for the ki-67 and active caspase-3. All data presented are the average 
from triplicate experiments. 
 
Cell pretreatment washout experiments and dilution assays 
Cytotoxicity was assessed further in pretreatment or washout experiments involving 
human malignant U-87 MG cells (Fig. 3) and normal MRC-5 cells (Fig. 4). Cells 
were pretreated at the previously determined IC50 concentrations of BOR2, BOR3 and 
BOR4 for 24, 48 or 72 h (marked in Figure 2 as -24, -48, -72 hrs). The replenishment 
of cells (wash-out time point marked as 0) was achieved by washing out the cells 
twice with PBS and then with fresh DMEM medium containing no DLC-carborane 
compounds. Each cell culture was allowed to grow for 120 h; cell density and cell 
death were monitored every 24 h. 
The notable capability of normal MRC-5 cells to regain their full proliferation 
potential prompted further investigation through dilution assays in which the cell 
culture was re-suspended and transferred to an expanded cell culture surface with a 
larger volume of medium. At 72 h, the total volume (1 mL) of each cell culture was 
transferred from the 24 well tissue cell culture plate to a (60 × 15) mm plate with a 
total volume of 4 mL (Figure 4C). After 48 h had elapsed, the cell culture was diluted 
further to a final volume of 10 mL (P10 cell culture dish) and allowed to grow for a 
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further 48 h (time point of 168 h). Cell death was determined by means of the Trypan 
blue staining method [21]. 
 
Cytoplasmic RNA isolation and real-time polymerase chain reaction (qPCR) 
RNA isolation from cell cultures that had been treated with DLC-carboranes was 
carried out by applying an in-house manual protocol based on the phenol-chloroform 
liquid-liquid extraction of cytoplasmic RNA [21]. The two-step qPCR analysis was 
performed according to the KAPA SYBR FAST qPCR Kit (ΚΚ4602-
KAPABIOSYSTEMS) manufacturer instructions. Acidic phenol retained RNA 
preferentially in the upper aqueous phase and minimized RNase activity. After 
isolation, RNA was tested qualitatively and quantitatively, respectively by a gel 
electrophoresis assay and by means of the Thermo Scientific NanoDrop 2000 
spectrophotometer. Template RNA (200 ng) was used in a cDNA synthesis reaction 
by following the protocol of the QuantiTect Reverse Transcription Kit (QIAGEN) for 
cDNA synthesis. A dilution of 1:20 was carried out in order for samples to reach the 
desirable amplification plots within the range of 25 to 35 Cts (Cycle threshold) for 
each gene tested. The two-step qPCR analysis was performed according to the KAPA 
SYBR FAST qPCR Kit (ΚΚ4602-KAPABIOSYSTEMS) manufacturer instructions. 
To ensure the absence of non-desirably amplified products, PCR samples were 
additionally analyzed by 1% w/v agarose gel electrophoresis, stained with ethidium 
bromide and photographed under UV light exposure (data not shown). The primer 
sequences applied in qPCR analysis are presented in Supplemental Table S1. 
 
RESULTS 
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DLC-functionalized carboranes exhibit selectivity in their cytotoxicity profile 
and behavior towards cancer cells 
DLC-carborane compounds, [BOR2, (o-carboranyl triphenyl phosphonium methylene 
bromide); BOR3, (nido-carborane salt of tetraphenylphosphonium); BOR4, (nido-
carborane salt of dequalinium); and BOR5, (nido-carborane salt of rhodamine B)], 
with a known propensity to accumulate selectively in cancer cells [20] were selected 
for pharmacological evaluation along with compound BOR, [1,7-bis(3-
hydroxypropyl)-meta-carborane], which was used as control (Figure 1). To estimate 
IC50 values (Table 1), two malignant (U-87 MG and HSC-3) and two normal (Vero 
and MRC-5) cell lines were separately incubated for 48 h with each DLC-carborane at 
a specified concentration in the range 5x10⁻7 M to 1x10-4 M (Supplementary Figures 
S1-S5). Even at high concentrations, BOR exhibited no evidence of cytotoxicity 
against the malignant and normal cell lines employed for the assessment (Table 1). By 
contrast, the four DLC-carboranes, exhibited a concentration-dependent cytotoxicity 
profile with marked differences in potency between malignant and normal cells 
(Supplementary Figures S1-S5); the most cytotoxic DLC-carborane is BOR4. 
Reflective of a 5-6 fold difference in potency between malignant and normal cells, the 
IC50 values of BOR2 were 8.35x10
-6
 M in U-87 MG and 8.18x10
-6
 M in HSC-3 cells, 
and 2.1x10
-5
 M and 1.45x10
-5
 M, respectively in MRC-5 and Vero cells. Indicative of 
10-80 fold differences in potency, corresponding values for BOR3 were 4.5x10
-6
 M 
(U-87 MG), 2.8x10
-6
 M (HSC-3), 8.1x10
-5
 M (MRC-5) and >10
-4
 M (Vero). For 
BOR4, values were determined at 3.2x10
-6
 M (U-87 MG), 3.3x10
-6
 M (HSC-3), 5x10
-
5
 M (MRC-5) and 5.6x10
-6
 M (Vero), corresponding to 2 fold differences in potency. 
BOR5, which exhibited values of 4.5x10
-5
 M (U-87 MG), 8.13x10
-5
 M (HSC-3), 
2.4x10
-5
 M (MRC-5) and 7.15x10
-5
 M (Vero), displayed not substantial differences in 
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cell-growth inhibitory potency among the various cultures. Notably, the proportion of 
dead cells measured in cultures of malignant cells was seen to increase only at the 
higher concentrations employed (5x10-
5
 M and 1x10
-4
 M); this effect was more 
pronounced in samples that had been treated with BOR2 and BOR4 (data not shown). 
In view of the observed cancer cell selectivity, an attempt was made to assess the 
cytotoxicity behavior of the most promising DLC-carboranes, BOR2, BOR3 and 
BOR4, on CSCs cultures. The IC50 values (Supplementary Figure S6; Table 1) 
determined in primary GBM EGFR
neg
 and EGFR
pos
 CSCs provide further evidence 
that the DLC-carborane compounds exhibit a highly selective cytotoxicy profile. 
BOR3, especially, is characterized by an IC50 value which is about 500 fold lower for 
CSCs as compared with that for the normal cells. 
 
DLC-carboranes inhibit the proliferation potential of primary GBM CSCs 
without activating apoptosis 
To assess the cell proliferation potential of primary GBM CSCs that had been treated 
with DLC-carboranes, the levels of the proliferation marker ki-67 and that of the 
active caspase-3 apoptosis marker were examined by means of specific ICC assays. 
Since only EGFR
neg
 cultures grow as monolayers, these were selected for testing and 
incubated with the IC50 concentrations of the most two potent DLC-carboranes, BOR3 
and BOR4, for either 24 or 48 h. Figure 2 shows that at both time points under 
consideration, the levels of the ki-67 proliferation marker were markedly reduced in 
cell cultures relative to those of the control (untreated) cells. Indeed, the level of ki-67 
expression was assessed quantitatively by counting at least 1000 cells. Notably, the 
ki-67 expression level in treated cultures was seen to be 50-60 % lower after 24 - 48 h 
of treatment (Figure 2G). Since, ki-67 is exclusively expressed in proliferating cells 
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and it is detected only during the active cell cycle phases (it is not detectable in the G0 
phase) [26], the results confirm the capability of DLC-carboranes to cause growth 
inhibition in primary GBM CSCs. Since no detectable levels of active caspase-3 have 
been observed, it is assumed that although these compounds do not induce apoptosis 
in CSCs, they have a profound inhibitory cell growth potential. 
 
Selective recapitulation of cell proliferation potential consequent to DLC-
carborane pretreatment of normal cells 
The pharmacological screening observation that the DLC-carboranes under 
consideration induced limited cell death at concentrations close to their IC50 values, 
prompted pretreatment washout experiments. To this end, the cell cultures were each 
treated continuously at the IC50 concentrations of BOR2, BOR3, BOR4 and BOR5 for 
24, 48 or 72 h, and subsequently, at the time point referred as “0”, a washout step was 
introduced by allowing cells to grow in agents-free medium. To facilitate the 
determination of the logarithmic and plateau phases of cell growth, an untreated 
control culture was allowed to grow in parallel to the same sequence of treatments. A 
typical pretreatment washout experiment mirroring the behavior of U-87 MG and 
MRC-5 cells pretreated with BOR2 is presented in Figure 3 and 4, respectively. The 
proliferation of U-87 MG cells is irreversibly inhibited, even after the washout step 
(Figure 3A), and the level of cell death seen in culture is very low (Figure 3B).This 
effect is independent of the timescale of the pretreatment period (24, 48 or 72 h). The 
observation that untreated control U-87 MG cells exhibit only 20% cell death after 
120 h, when maximum confluency and nutrient starvation exists in culture, suggests 
that these cells enter cell cycle arrest. Normal MRC-5 cells are characterized by a 
different profile: the initial inhibition of cell growth, consequent to exposure to DLC-
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carboranes at IC50, is followed, soon after transfer to BOR2-free medium by a 
proliferation phase, which is in turn followed by a plateau phase (Figure 4A). Such 
behavior unveils the capability of MRC-5 cells to recapitulate their potential to 
proliferate even after exposure to BOR2. Indicative of an inherent capability to regain 
its full proliferation potential, the MRC-5 cell culture that had been pretreated for 24 h 
before being moved to BOR2-free medium achieved similar cell density to that of the 
untreated control culture. The proportion of cell death in cultures exposed to 
prolonged treatments is markedly higher, but this may be explained, at least in part, 
by issues of confluency and nutrient starvation that arise consequent to the very 
considerable increase in cell numbers (Figure 4B,D). Notable is the behavior of U-87 
MG and MRC-5 cells at the plateau phase of their growth in culture (Figure 3B and 
4B); the response of normal MRC-5 is in marked contrast to that of malignant U-87 
MG cells, which are unable to overcome the cytotoxicity effect triggered by the 
BOR2 pretreatment. To assess the capability of normal MRC-5 cells to regain their 
proliferative potential further, an experiment was designed involving the serial 
medium dilution of cells for the purpose of ensuring the continuous logarithmic 
growth of cell cultures. The data obtained revealed (Figure 4C) that the cell 
proliferation capability of pretreated MRC-5 cells occurs in a time-dependent manner. 
All pretreated cell cultures were characterized by a marked increase in cell 
proliferation in the time period between 72 and 168 h. The increase observed for the 
72 h BOR2-pretreated cell culture was ca. 70 % while that at 24 and 48 h was ca. 
95%. The proportion of cell death in the logarithmic-phase serially diluted cultures 
was markedly lower than that of those grown continuously in the original plate from 
the initial cell cultures (cf. Figure 4D and 4B). Since similar behavior was observed in 
experiments involving the assessment of BOR3 and BOR4 against U-87 MG and 
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MRC-5 cells (Supplementary Figures S7 and S8) it is assumed that these effects are 
integrally related to chemical structural features of the carborane compounds under 
evaluation. To confirm the capability of normal cells to regain their proliferative 
potential, another cell line was tested against the most cytotoxic DLC-carborane 
(BOR4), namely: normal monkey Vero cells. Again, the results revealed the 
capability of BOR4-pretreated Vero cells to regain their proliferation capacity 
following transfer and culturing in BOR4-free medium (data not shown). 
 
The cancer-cell-specific cytotoxicity behavior of DLC-carboranes is mediated by 
activation of the p53/p21 signaling pathway 
The evaluations of cell kinetics from the continuous and pretreatment washout 
treatments with DLC-carboranes prompted an attempt to elucidate the underlying 
molecular mechanisms that contribute to the observed cellular responses through the 
qPCR analysis of the expression level of cell cycle and apoptosis related genes. To 
this end, the malignant U-87 MG and normal MRC-5 cells were each treated 
continuously for 24 or 72 h with the IC50 concentrations of BOR2, BOR3 and/or 
BOR4 (Table 1). The assessment was focused on 14 genes (including the 
housekeeping β-actin; Supplementary Table S1; Figure 5 and 7). Considering the 
pronounced changes in the gene expression profiles upon continuous treatment of 
cells with DLC-carboranes, a complementary set of growth kinetics experiments was 
performed in order to investigate the effects of pretreatment washout experiments at 
the molecular level. The analysis of cultures that had been pretreated with DLC-
carboranes (48 h) was carried out at 48 and at 72 h following the growth of cells in 
media that were free from DLC-carboranes (Figure 6 and 8). U-87 MG cells exhibits 
a similar, time-dependent profile irrespective of the DLC-carborane used (BOR2, 
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BOR3 and/or BOR4) for their continuous treatment (Figure 5A-C). Cells treated with 
the IC50 concentration of BOR2 exhibit an increase in the level of expression of 
apoptotic caspase-8, caspase-3 and bax genes, and also an increase in the expression 
of the bcl-2 anti-apoptotic gene. The marked increase in the levels of p53 and p21 
mRNA (Figure 5A) indicates the activation of the p53/p21 signaling pathway. The 
continuous treatment of U-87 MG cells at the IC50 concentration of BOR3 indicates a 
gene expression profile that is similar apart from the notable exception in the 
expression of caspase-8 (Figure 5B). The continuous treatment of U-87 MG cells with 
the IC50 concentration of BOR4 also induces an augmentation in the level of 
expression of apoptotic caspase-8, bad and bax genes, a parallel increase in the 
expression of the anti-apoptotic bcl-2 gene and an extensive increase of the expression 
of the p53/p21 gene axis (Figure 5C). Especially for BOR4 which is the more potent 
compound in cell-growth inhibitory capacity, by repeating such analysis in U-87 MG 
cells but at much lower than IC50 concentration (1x10
-6
 M) of BOR4 was shown a 
concentration-dependent effect on these gene expression changes (data not shown). 
Notably, during the pretreatment washout experiment (Figure 6A-C) the molecular 
analysis of U-87 MG cells that had been pretreated with BOR2 or BOR3 revealed a 
similar pattern of gene expression: the gene expression levels of c-myc, cyclin D1, 
Cdk4, p53 and p21 increased, whereas those of bcl-2 and bax decreased. The analysis 
of BOR4-pretreated U-87 MG cells indicated highly augmented levels of gene 
expression in the pro-apoptotic bad gene and also in the p53/p21 gene axis. On 
contrary, the gene expression profiling of MRC-5 cells that had been exposed to 
continuous treatment with DLC-carboranes (BOR2, BOR3 and/or BOR4) at their IC50 
concentration does not reveal any major effects (Figure 7A-C). From the panel of 14 
genes analyzed, in MRC-5 cells only five cell cycle and apoptosis related genes were 
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seen to be amplified by qPCR, namely: Cdk2, Cdk6, bad, bax and bcl-2. Consistent 
with literature reports [27-31] the gene expression levels of p53, p21, caspase-3-8-9, 
cyclin D1, Cdk4 and c-myc were repeatedly undetectable in untreated (control) MRC-
5 cells. In accordance with their cell kinetics profile of MRC-5 cells in culture, no 
significant differences were observed in the levels of gene expression during the 
pretreatment washout experiments (Figure 8) as compared with the untreated control 
cultures. For purposes of comparison with changes seen in normal MRC-5 cells, a 
similar molecular analysis protocol was adopted in a study involving normal Vero 
cells that had been treated with the IC50 concentration of BOR4, either continuously 
or upon pretreatment wash out methodology (data not shown). Consistent with the 
observed differences in the effects induced by DLC-carboranes to the gene expression 
profiles of normal and malignant cells, the profile of treated Vero cells was seen to 
coincide with that of MRC-5 cells, and consequently to be markedly different to that 
yielded by the similar treatment of malignant U-87 MG cells. 
 
DISCUSSION 
It is widely understood that cancer is a heterogeneous disease in which tumor cell 
heterogeneity contributes to therapy failure and disease recurrence [5]. In this study, 
cellular and molecular pharmacological data demonstrate that DLC-carborane 
compounds target cancer and primary GBM CSCs highly selectively and also that 
these agents exert a very significant pharmacological behavior while sparing normal 
cells. Based on the principle of the elimination of CSCs toward achieving patient 
long-term cure rates in the clinical setting [3,6,7], it is of significance that DLC-
carborane compounds exert such remarkable effect on GBM CSC lines. The effect is 
most meaningfully demonstrated by the determined IC50 values, which are markedly 
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lower than those calculated for normal cells (ca. 10-500 fold difference in potency), 
and further supported by pretreatment and dilution assays. Moreover, the observation 
that the tested DLC-functionalized carboranes exhibit selective cytotoxicity towards 
primary GBM CSCs indicates their potential to drive cytotoxic actions to 
heterogeneous tumor cell subpopulations. This is an issue of some significance since 
such genetically- and molecularly-diverse cell types crucially restricts the therapeutics 
outcome and correlates with the emergence of cancer drug resistance [8]. Notably, 
following their pretreatment with DLC-carboranes, only normal cells were seen to 
recapitulate their full proliferation potential in media that were free from these 
compounds; this effect was verified through dilution assays. The selective effect of 
the functionized carboranes appears to be linked to their DLC moiety, which elicits a 
cytotoxic response with a therapeutic potential through mitochondrial targets [11,18], 
since: a) triphenylphosphonium ions (TPPs), have been exploited as small molecule 
directing groups to achieve mitochondrial delivery [17]; b) rhodamine functionalities 
have been  utilized in mitochondria-specific dyes [11,15,20]; and, c) dequalinium 
(DQA) has been evaluated in a therapeutic approach for the treatment of B-cell 
chronic lymphocytic leukemia (B-CLL), acute promyelocytic leukemia (APL) and 
hepatocellular carcinoma (HCC) [32,33]. 
To gain insight on the molecular mechanisms underlying the pharmacological profile 
of DLC-functionalized carboranes, the treatment of both malignant and normal cells 
was conducted at the experimentally calculated IC50 values for each cell type, while 
higher concentrations are applied for normal cell cultures. Even under this treatment 
regime, however, a marked gene expression augmentation of the p53/p21 axis was 
seen to occur in malignant cells only (U-87 MG). The increased levels of p53 and p21 
gene expression, especially in the case of BOR4-treated U-87 MG cells, suggests that 
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the stimulus that malignant cells receive during their treatment with DLC-carboranes 
activates the tumor suppressor protein p53, which mediates the DNA damage-induced 
checkpoint mechanism through the trans-activation of growth inhibitory genes, such 
as p21. This in turn leads malignant cells to p53-dependent G1 growth arrest [34-38]. 
It is known that cellular progression halts until genetic errors are fixed or the cellular 
environment becomes permissive to the proper DNA synthesis and cell cycle 
progression [38-40], but this however, was not observed on treatment with DLC-
carboranes, since qPCR analysis revealed the gene expression profile of malignant 
cells had not been reversed after the removal of agents from the culture. In the case of 
BOR4, an even more augmented level of p53/p21 gene expression was noticed after 
its removal, despite the parallel increase in the expression level of cell cycle driving 
genes, like c-myc, cyclin D1 and cdk4. This observation suggests that malignant cells 
were unsuccessful in their attempt to overcome their p53/p21-mediated proliferation 
blockade by transcriptionally activating specific cycle-related gene cascade 
mechanisms [41]. These findings suggest the continuing effect of DLC-functionalized 
carboranes, like BOR4, on malignant cells after their removal from the culture. The 
permanency of cytotoxic damage to tumor cells is indicated by the differences in gene 
expression levels observed in parallel experiments involving normal cells. 
Alternatively, the unmatched gene expression profiles seen in glioblastoma U87 MG 
and normal MRC-5 cell cultures exposed to carboranes along with their sensitivity to 
respond to proliferation (high range in IC50 values) and cell-cycle behavior in 
pretreatment/washout experiments (ability only for normal cells to recapitulate growth 
rates), imply that the underlying molecular mechanisms trigger different responses to 
crucial cellular decisions. For example, p53 induces tissue-specific apoptosis through 
alternative mechanisms mediated by transcription-dependent (e.g. trans-activation of 
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bax or trans-repression of bcl-2) or transcription-independent (mitochondria-targeted 
repression of bcl-2 and bcl-XL) pathways [42, 43]. To this end, the p53-mediated 
growth inhibitory signaling has been shown to be affected by the mutational status of 
p53 gene in various cells types, a fact leading to modified transcriptional capacity to 
target gene activation as well as to cell cycle regulatory gene suppression [44]. The 
molecular profiling analysis has shown that only exposure of U87 MG cells to 
carboranes (BOR2, BOR3, BOR4) resulted in transcriptional activation of genes 
related to cell-cycle arrest (e.g. p53/p21 axis), to apoptosis (bax, bad, caspases 3 and 
9), to survival (e.g. bcl-2), as well as to mitogenesis (e.g. c-myc, cyclin D1, cdk4). 
Noteworthy, in carborane-treated cells the expression of both pro-apoptotic (bax, bad) 
and pro-survival genes (bcl-2) of bcl-2 family members have been activated. 
Although the observed pattern of gene expression implies signaling pathways with 
opposing cellular response functions, however, it has resulted in profound growth-
arrest in culture without the activation of apoptosis mechanisms. Moreover, upon the 
pretreatment experiments, (where after their initial exposure to carboranes, U87 MG 
cells are grown to agents-free medium), it has been noticed that also the expression of 
mitogenic-related genes (c-myc, cyclin D1 and cdk4) is increased, in parallel with the 
transcriptional activation of p53/p21axis that was also seen in these cultures. The 
latter, is an interesting observation that can be explained as an unsuccessful attempt of 
cells after the removal of carboranes form the culture to overcome the agent-triggered 
cell-cycle arrest mediated by p53/p21. Importantly enough, through these opposing 
molecular pathways impinging on to either proliferation and survival, or growth arrest 
and apoptosis [45-47], the treatment of glioblastoma U87 MG cultures with 
carboranes leads to a such functional balance in gene expression that permanently 
leads them to inability for cell cycling and division. Overall, these bifunctional acting 
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carborane compounds represent a new class of anticancer agents whose 
pharmacological efficacy and safety profiles deserve further clinical investigation and 
verification. Accordingly, the pharmacological evaluation of the DLC-carboranes 
indicates not only their potential value to BNCT as previously shown, [20] but also 
implies their remarkable therapeutic potential as stand-alone anticancer drugs. 
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Table 1. IC50 values of the bifunctional carborane compounds tested in various normal, cancer and primary GBM CSCs. 
Cell type IC50 BOR2 
(M) 
IC50 BOR3 
(M) 
IC50 BOR4 
(M) 
IC50 BOR5 
(M) 
IC50 BOR 
(M) 
U-87 MG 
Human epithelial glioblastoma grade IV; astrocytoma cells 
8.35x10
-6
 4.5 x 10
-6
 3.2 x 10
-6
 4.5 x 10
-5
 > 10
-4
 
HSC3 
Human oral squamous carcinoma cells 
8.18x10
-6
 2.8 x 10
-6
 3.3 x 10
-6
 8.13 x 10
-5
 > 10
-4
 
MRC-5 
Human normal lung fibroblast cells 
2.1 x 10
-5
 8.1 x 10
-5
 5 x 10
-6
 2.4 x 10
-5
 > 10
-4
 
Vero 
Monkey normal kidney cells 
1.45 x 10
-5
 > 10
-4
 5.6 x 10
-6
 7.15 x 10
-5
 > 10
-4
 
EGFR
neg 
Human brain cancer stem cells 
2 x 10
-6
 7 x 10
-7
 6 x 10
-7
 N.A. > 10
-4
 
EGFR
pos
 
Human brain cancer stem cells 
2.5 x 10
-6
 4.5 x 10
-6
 1.9 x 10
-6
 N.A. > 10
-4
 
       N.A.: Not analyzed. 
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LEGENDS TO FIGURES 
Figure 1: Chemical structures of delocalized lipophilic cation-functionalized carboranes. 
The structure of tested compounds: BOR (1,7-bis(3-hydroxypropyl)-meta-carborane), 
BOR2 (o-carboranyl triphenyl phosphonium methylene bromide), BOR3 (nido-
carborane salt of tetraphenylphosphonium), BOR4 (nido-carborane salt of dequalinium) 
and BOR5 (nido-carborane salt of rhodamine B).  
 
Figure 2: Assessment of levels of the ki-67 proliferation marker in primary GBM CSCs 
grown in the presence of DLC-carboranes. EGFR
neg
 primary GBM CSCs were each 
treated for 24 h (at left) and/or 48 h (at right) with the IC50 concentrations of BOR3 
(7x10
-7
 M) and BOR4 (6x10
-7
 M), Table 1, before the measurement of ki-67 levels (see 
“Materials and Methods”). Panels A and B, untreated (control) cultures; Panels C and D, 
BOR3-treated cultures; Panels E and F, BOR4-treated cultures; Panels A, C and E, 
DAPI-stained cell nuclei; Panels B, D and F, ki-67 expression levels; Panel G, 
quantification of ki-67 by means of the data obtained from panels B, D and F. The 
results are presented as a percentage of the ki-67 expression determined for untreated 
control cultures and represent the mean (± SD) of two independent experiments. 
Statistical analysis was performed by paired t-test. A significance level of p < 0.05 
denoted significance. 
 
Figure 3: Assessment of cell proliferation potential of U-87 MG cells in culture 
following their pretreatment with BOR2 for specified time intervals. Malignant human 
U-87 MG cells that had been grown in culture were treated with the IC50 concentration 
of BOR2 (8.35x10
-6
 M) for specified time intervals (-24, -48 -72 h; pretreatment). After 
this time, cells were washed out (time 0) and allowed to grow in culture in BOR2-free 
medium. Cell growth (Panel A) and cell death (Panel B) were assessed as described 
under “Materials and Methods”. The pretreatment of U-87 MG cells with BOR2 
inhibited the cells capacity to proliferate, even when cells were grown in agents-free 
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media. The data shown above indicate a representative experiment where three 
independent measurements were used to calculate the mean (± SD). A biological 
replication of this experiment was carried out twice with similar results. Statistics was 
performed by paired t-test. A significance level of p < 0.05 denoted significance. 
 
Figure 4: Assessment of cell proliferation potential of MRC-5 cells in culture following 
their pretreatment with BOR2 for specified time intervals. Normal human MRC-5 cells 
that had been grown in culture were treated with the IC50 concentration of BOR2 
(2.1x10
-5
 M) for specified time intervals (-24, -48 -72 h; pretreatment). After this time, 
cells were washed out (time 0) and allowed to grow in culture in BOR2-free medium. 
Cell growth (Panel A) and cell death (Panel B) were assessed as described under 
“Experimental section”. In BOR2-free media, BOR2-pretreated MRC-5 cells 
recapitulated their full proliferation potential, even reaching the plateau phase of growth 
at which cell death occurs due to confluency (Panel B). To establish the conditions under 
which cells exhibit unrestricted proliferation capacity, BOR2-pretreated MRC-5 cells 
were subjected to proper dilution assays (see at “Materials and Methods”). Panel C: 
Time-dependent kinetics of cell growth; the first arrow pinpoints cell cultures that had 
been transferred from the 24-well plate (1 mL volume) to the (60 x 15) mm plate (4 mL 
volume); the second arrow is directed to cells that had been transferred from the (60 x 
15) mm plate (4 mL volume) to P10 culture dish (10 mL volume). Since cells do not 
reach a plateau phase of growth, cell death is minimal (Panel D). The data shown above 
indicate a representative experiment where three independent measurements were used 
to calculate the mean (± SD). A biological replication of this experiment was carried out 
twice with similar results. Statistics was performed by paired t-test. A significance level 
of p < 0.05 denoted significance. 
 
Figure 5: qPCR analysis of U-87 MG cells exposed to DLC-carboranes. The gene 
expression profiles for proliferation- and/or apoptosis-related molecules in malignant U-
31 
 
87 MG cells that had been treated with the IC50 concentrations of BOR2 (Panel A), 
BOR3 (Panel B) or BOR4 (Panel C) for 24 h or 72 h is presented. The analysis was 
carried out with qPCR with the primers shown in Supplementary Table S1, as described 
under “Materials and Methods”. The data shown above indicate a representative 
experiment where three independent measurements were used to calculate the mean (± 
SD). A biological replication of this experiment was carried out at least twice with 
similar results. Statistics was performed by paired t-test. A significance level of p < 0.05 
denoted significance. 
 
Figure 6: qPCR analysis of U-87 MG cells pretreated with DLC-carboranes and then 
allowed to grow under agents-free conditions. Gene expression molecular analysis of 
malignant U-87 MG cells that had been pretreated for 48 h with BOR2 (Panel A), BOR3 
(Panel B) or BOR4 (Panel C), washed out and allowed to grow under agent-free 
conditions for an additional 48 or 72 h. The analysis was performed as shown under 
Figure 5. The data shown above indicate a representative experiment where three 
independent measurements were used to calculate the mean (± SD). A biological 
replication of this experiment was carried out at least twice with similar results. Statistics 
was performed by paired t-test. A significance level of p < 0.05 denoted significance. 
 
Figure 7: qPCR analysis of MRC-5 cells exposed to DLC-carboranes. Similarly to the 
analysis shown under Figure 5, the gene expression profiles for proliferation- and 
apoptosis-related molecules in normal human MRC-5 cells that had been treated with the 
IC50 concentrations of BOR2 (Panel A), BOR3 (Panel B) or BOR4 (Panel C) for 24 h or 
72 h is presented. The data shown above indicate a representative experiment where 
three independent measurements were used to calculate the mean (± SD). A biological 
replication of this experiment was carried out at least twice with similar results. Statistics 
was performed by paired t-test. A significance level of p < 0.05 denoted significance. 
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Figure 8: qPCR analysis of MRC-5 cells pretreated with DLC-carboranes and then 
allowed to grow under agents-free conditions. Similarly to the analysis shown under 
Figure 6, the gene expression molecular analysis of MRC-5 cells that had been 
pretreated for 48 h with BOR2 (Panel A), BOR3 (Panel B) or BOR4 (Panel C), washed 
out and allowed to grow under agent-free conditions for an additional 48 or 72 h. The 
data shown above indicate a representative experiment where three independent 
measurements were used to calculate the mean (± SD). A biological replication of this 
experiment was carried out at least twice with similar results. Statistics was performed 
by paired t-test. A significance level of p < 0.05 denoted significance. 
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Supplementary Table S1. Primer sequences used to analyze gene expression 
profiles by qPCR 
 
HGNC Gene Primer code Primer sequence PCR product size 
MYC 
 
(c-myc) 
hCmyc RT F 5'- AGGAGAATGTCAAGAGGCGA -3' 119bp 
hCmyc RT R 5'- GGCCTTTTCATTGTTTTCCA -3' 
CASP8 
 
(caspase 8) 
hCasp8 RT F 5'- GATGACATGAACCTGCTGGA-3' 111bp 
hCasp8 RT R 5'- CAGGCTCTTGTTGATTTGGG -3' 
CCND1 
 
(cyclin D1) 
hCyclD1 RT F 5'- CTGCGAAGTGGAAACCATC -3' 117bp 
hCyclD1 RT R 5'- TTGAAGTAGGACACCGAGGG -3' 
CDK6 
 
(cdk6) 
hCdk6 RT F 5'- TGCACAGTGTCACGAACAGA -3' 150bp 
hCdk6 RT R 5' ACCTCGGAGAAGCTGAAACA -3' 
CDK2 
 
(cdk2) 
hCdk2 RT F 5'-TTGTCAAGCTGCTGGATGTC -3 126bp 
hCdk2 RT R 5'- TGATGAGGGGAAGAGGAATG -3' 
CDK4 
 
(cdk4) 
hCdk4 RT F 5-ACCAGATGGCACTTACACCC-3 148bp 
hCdk4 RT R 5'- CCACAGAAGAGAGGCTTTCG -3' 
CASP3 
 
(caspase 3) 
hCasp3 RT F 5'-GGTTCATCCAGTCGCTTTGT -3' 100bp 
hCasp3 RT R 5'- AATTCTGTTGCCACCTTTCG -3' 
BAD 
 
(bad) 
hBAD RT F 5'-CAGATCCCAGAGTTTGAGCC-3' 156bp 
hBAD RT R 5'-CTGCTCCTGCTGGTGACTG-3' 
CASP9) 
 
(caspase 9) 
hCasp9 RT F 5'-TCGAAGCCAACCCTAGAAAA-3' 110bp 
hCasp9 RT R 5'- CCTCCAGAACCAATGTCCAC-3' 
CDKN1A 
 
(p21) 
hp21 RT F 5'- GAGCGATGGAACTTCGACTT -3' 101bp 
hp21 RT R 5'-GTGGGAAGGTAGAGCTTGGG -3' 
BCL2 
 
(bcl-2) 
hBcl2 RT F 5'-ACTTCGCCGAGATGTCCA  -3' 123bp 
hBcl2 RT R 5'-CAAAGAAGGCCACAATCCTC  -3' 
BAX 
 
(bax) 
hBAX RT F 5'-TCTGACGGCAACTTCAACTG -3' 132bp 
hBAX RT R 5'-GAGGAAGTCCAATGTCCAGC  -3' 
TP53 
 
(p53) 
p53 F 5'- CCTTCCCAGAAAACCTACCAG-3' 230bp 
p53 R 5'- CCTCACAACCTCCGTCATG-3' 
ACTB 
 
(actin, beta) 
b- actin hmF 5'-TTGCTGACAGGATGCAGAAG-3' 147bp 
b- actin hmR 5'-TGATCCACATCTGCTGGAAG-3' 
 
2 
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Supplementary Figure S1. Assessment of the cell growth and the proportion of dead 
cells in cultures of malignant (U-87MG, HSC-3) and normal (MRC-5 and Vero) cell 
lines   grown   in   culture   at   various   concentrations   of   compound   BOR.   The 
measurements were carried out as described under “Experimental section”. 
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Supplementary Figure S2. The Assessment of the cell growth and the proportion of 
dead cells in cultures of malignant (U-87MG, HSC-3) and normal (MRC-5 and Vero) 
cell  lines  grown  in  culture  at  various  concentrations  of  compound  BOR2.  The 
measurements were carried out as described under “Experimental section”. 
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Supplementary Figure S3. Assessment of the cell growth and the proportion of dead 
cells in cultures of malignant (U-87MG, HSC-3) and normal (MRC-5 and Vero) cell 
lines   grown   in   culture   at   various   concentrations   of   compound   BOR3.   The 
measurements were carried out as described under “Experimental section”. 
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Supplementary Figure S4. Assessment of the cell growth and the proportion of dead 
cells in cultures of malignant (U-87MG, HSC-3) and normal (MRC-5 and Vero) cell 
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lines   grown   in   culture   at   various   concentrations   of   compound   BOR4.   The 
measurements were carried out as described under “Experimental section”. 
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Supplementary Figure S5. Assessment of the cell growth and the proportion of dead 
cells in cultures of malignant (U-87MG, HSC-3) and normal (MRC-5 and Vero) cell 
lines   grown   in   culture   at   various   concentrations   of   compound   BOR5.   The 
measurements were carried out as described under “Experimental section”. 
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Supplementary  Figure  S6.  Cytotoxicity  assessment  of  DLC-carboranes  in 
primary GBM CSCs growing either as monolayers or as neurospheres. 
Upper  panels:  The  EGFR
neg   
primary  GBM  CSCs,  which  grow  in  culture  as 
 
monolayers, were treated at specified concentrations of BOR2, BOR3 and BOR4 for 
 
48  h.  Cell  proliferation  was  assessed  by  the  MTT  assay,  as  described  under 
“Experimental section”. The data shown represent the mean values (±SD) of three 
independent experiments. Statistics was carried out by paired t-test. A significance 
level of p < 0.05 denoted significance. Lower panels: The EGFR
pos 
primary GBM 
CSCs, which grow in culture as neurospheres, were exposed for 48 h to the specified 
concentrations of BOR2, BOR3 and BOR4. Cell proliferation was assessed by means 
of  the  MTT  assay,  as  described  under  Materials  and  Methods.  The  data  shown 
represent  the  mean  values  (±SD)  of  three  independent  experiments.  Statistical 
analysis was performed by paired t-test. A significance level of p < 0.05 denoted 
significance. 
 
8 
 
47 
 
 
 
Supplementary Figure S7. Assessment of cell proliferation potential of U-87 MG 
cells in culture following their pretreatment with BOR3 and BOR4. Malignant 
human U-87 MG cells that had been grown in culture were treated with the IC50 
concentration of BOR3 (4.5x10
-6  
M; panels A and B) and/or of BOR4 (3.2x10
-6  
M; 
 
panels C and D) at time intervals (-24, -48 -72 h; pretreatment). After this time, cells 
were washed out (time 0) and allowed to grow in culture in agent-free medium. Cell 
growth (Panels A and C) and cell death (Panels B and D) were assessed, as described 
under “Materials  and  Methods”.  The  data  shown above  indicate  a  representative 
experiment where three independent measurements were used to calculate the mean 
(± SD). A biological replication of this experiment was carried out twice with similar 
results. Statistics was performed by paired t-test. A significance level of p < 0.05 
denoted significance. 
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Supplementary Figure S8. Assessment of cell proliferation potential of 
MRC-5 cells  in  culture  following  their  pretreatment  with  BOR3  and  
BOR4.  Normal human  MRC-5  cells  that  had  been  grown  in  culture  were  
treated  with  the  IC50 
concentration of BOR3 (8.1x10
-5  
M; panels A and B) and/or of BOR4 (5x10
-6  
M; 
 
panels C and D) at time intervals (-24, -48 -72 h; pretreatment). Afterwards, 
cells were washed out (time 0) and allowed to grow in culture in agent-free 
medium. Cell growth (Panels A and C) and cell death (Panels B and D) were 
assessed as described under “Materials  and  Methods”.  The  data  shown above  
indicate  a  representative experiment where three independent measurements were 
used to calculate the mean (± SD). A biological replication of this experiment was 
carried out twice with similar results. Statistics was performed by paired t-test. 
A significance level of p < 0.05 denoted significance. 
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